Novel Mutation at Cys225 in GNAO1-Associated Developmental and Epileptic Encephalopathies: Clinical, Molecular, and Pharmacological Profiling of Case Studies

Abstract

GNAO1-associated disorders have a large spectrum of neurological symptoms, from early-onset developmental and epileptic encephalopathies (DEE) to late-onset movement disorders. First reported in 2013 and now identified in around 400 cases worldwide, this disease is caused by dominant, mostly de novo missense mutations in GNAO1, the gene encoding the major neuronal G protein Gαo. Being the immediate transducer of a number of neuronal G protein-coupled receptors, Gαo plays crucial functions in brain development and physiology. Here, we discover a novel mutation site in GNAO1, Cys225 mutated to Tyr or Arg in pediatric individuals from France and China (p.(Cys225Tyr) and p.(Cys225Arg), respectively), leading to severe early-onset DEE. Molecular investigations characterize the novel pathogenic variants as deficient in the interactions with guanine nucleotides and physiological cellular partners of Gαo, with reduced stability and plasma membrane localization and a strong neomorphic interaction with the chaperone Ric8A. Salts of zinc, emerging as a promising targeted therapy for GNAO1-associated disorders, impose a previously unseen effect on the mutant Gαo, accelerating the loss of its ability to interact with guanine nucleotides. Our study, combining clinical, cellular, molecular, and modeling approaches, describes deep insights into molecular etiology and treatment perspectives of the novel form of GNAO1-associated disorders.

Keywords

developmental and epileptic encephalopathies / G protein / GNAO1 / molecular etiology / neomorphic mutations / rare disease

References

[1] R. Guerrini, V. Conti, M. Mantegazza, S. Balestrini, A. S. Galanopoulou, and F. Benfenati, “Developmental and Epileptic Encephalopathies: From Genetic Heterogeneity to Phenotypic Continuum,” Physiological Reviews 103, no. 1 (2023): 433-513.

[2] P. C. Sternweis and J. D. Robishaw, “Isolation of Two Proteins With High Affinity for Guanine Nucleotides From Membranes of Bovine Brain,” Journal of Biological Chemistry 259, no. 22 (1984): 13806-13813.

[3] W. J. Wolfgang, F. Quan, P. Goldsmith, C. Unson, A. Spiegel, and M. Forte, “Immunolocalization of G Protein Alpha-subunits in the Drosophila CNS,” Journal of Neuroscience 10, no. 3 (1990): 1014-1024.

[4] P. G. de Oliveira, M. L. S. Ramos, A. J. Amaro, R. A. Dias, and S. I. Vieira, “G(i/o)-Protein Coupled Receptors in the Aging Brain,” Frontiers in Aging Neuroscience 11 (2019): 89.

[5] V. L. Katanaev and M. Chornomorets, “Kinetic Diversity in G-protein-coupled Receptor Signalling,” Biochemical Journal 401, no. 2 (2007): 485-495.

[6] C. Lin, A. Koval, S. Tishchenko, et al., “Double Suppression of the Galpha Protein Activity by RGS Proteins. Research Support, Non-U.S. Gov't,” Molecular Cell 53, no. 4 (2014): 663-671.

[7] M. Novelli, S. Galosi, G. Zorzi, et al., “GNAO1-related Movement Disorder: An Update on Phenomenology, Clinical Course, and Response to Treatments,” Parkinsonism & Related Disorders 111 (2023): 105405.

[8] T. Wirth, G. Garone, M. A. Kurian, et al., “Highlighting the Dystonic Phenotype Related to GNAO1,” Movement Disorders 37, no. 7 (2022): 1547-1554.

[9] M. Sáez González, K. Kloosterhuis, L. van de Pol, F. Baas, and H. Mikkers, “Phenotypic Diversity in GNAO1 Patients: A Comprehensive Overview of Variants and Phenotypes,” Human Mutation 2023 (2023): 6628283.

[10] H. Feng, B. Sjögren, B. Karaj, V. Shaw, A. Gezer, and R. R. Neubig, “Movement Disorder in GNAO1 Encephalopathy Associated With Gain-of-function Mutations,” Neurology 89, no. 8 (2017): 762-770.

[11] B. S. Muntean, I. Masuho, M. Dao, et al., “Gαo Is a Major Determinant of cAMP Signaling in the Pathophysiology of Movement Disorders,” Cell Reports 34, no. 5 (2021): 108718.

[12] G. P. Solis, Y. A. Larasati, M. Thiel, A. Koval, A. Koy, and V. L. Katanaev, “GNAO1 Mutations Affecting the N-Terminal α-Helix of Gαo Lead to Parkinsonism,” Movement Disorders 39, no. 3 (2024): 601-606.

[13] A. Lasa-Aranzasti, Y. A. Larasati, J. da Silva Cardoso, et al., “Clinical and Molecular Profiling in GNAO1 Permits Phenotype-Genotype Correlation,” Movement Disorders 39, no. 9 (2024): 1578-1591.

[14] G. P. Solis, F. R. Danti, Y. A. Larasati, et al., “Clinical-molecular Profiling of atypical GNAO1 Patients: Novel Pathogenic Variants, Unusual Manifestations, and Severe Molecular Dysfunction,” Genes & Diseases (2025): 101522.

[15] Y. Larasati, M. Savitsky, A. Koval, G. P. Solis, J. Valnohova, and V. L. Katanaev, “Restoration of the GTPase Activity and Cellular Interactions of Gαo Mutants by Zn2+ in GNAO1 Encephalopathy Models,” Science Advances 8 (2022): eabn9350.

[16] V. L. Katanaev, J. Valnohova, D. N. Silachev, Y. A. Larasati, and A. Koval, “Pediatric GNAO1 Encephalopathies: From Molecular Etiology of the Disease to Drug Discovery,” Neural Regeneration Research 18, no. 10 (2023): 2188-2189.

[17] G. P. Solis, A. Koval, J. Valnohova, A. Kazemzadeh, M. Savitsky, and V. L. Katanaev, “Neomorphic Gαo Mutations Gain Interaction With Ric8 Proteins in GNAO1 Encephalopathies,” Journal of Clinical Investigation 134, no. 15 (2024): e172057.

[18] H. J. Muller, “Further Studies on the Nature and Causes of Gene Mutations,” Proceedings of the Sixth International Congress of Genetics, Ithaca, New York 1 (1932): 213-255.

[19] G. P. Solis, T. V. Kozhanova, A. Koval, et al., “Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights Into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease,” Cells 10, no. 10 (2021): 2749.

[20] K. M. Knight, E. G. Obarow, W. Wei, et al., “Molecular Annotation of G Protein Variants in a Neurological Disorder,” Cell Reports 42, no. 12 (2023): 113462.

[21] J. Domínguez-Carral, W. G. Ludlam, M. Junyent Segarra, et al., “Severity of GNAO1-Related Disorder Correlates With Changes in G-Protein Function,” Annals of Neurology 94, no. 5 (2023): 987-1004.

[22] H. Ham, H. Jing, I. T. Lamborn, et al., “Germline Mutations in a G Protein Identify Signaling Cross-Talk in T Cells,” Science 385, no. 6715 (2024): eadd8947.

[23] C. L. Larrivee, H. Feng, J. A. Quinn, et al., “Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone,” Journal of Pharmacology and Experimental Therapeutics 373, no. 1 (2020): 24-33.

[24] A. Koval, Y. A. Larasati, M. Savitsky, et al., “In-depth Molecular Profiling of an Intronic GNAO1 Mutant as the Basis for Personalized High-throughput Drug Screening,” Medicine 4, no. 5 (2023): 311-325.e7.

[25] Y. A. Larasati, G. P. Solis, A. Koval, et al., “Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R,” Cells 12, no. 20 (2023): 2469.

[26] G. G. Tall, A. M. Krumins, and A. G. Gilman, “Mammalian Ric-8A (synembryn) Is a Heterotrimeric Galpha Protein Guanine Nucleotide Exchange Factor,” Journal of Biological Chemistry 278, no. 10 (2003): 8356-8362.

[27] M. Gabay, M. E. Pinter, F. A. Wright, et al., “Ric-8 Proteins Are Molecular Chaperones That Direct Nascent G Protein α Subunit Membrane Association,” Science Signaling 4, no. 200 (2011): ra79-ra79.

[28] G. P. Solis, O. Bilousov, A. Koval, A. M. Luchtenborg, C. Lin, and V. L. Katanaev, “Golgi-Resident Galphao Promotes Protrusive Membrane Dynamics,” Cell 170, no. 5 (2017): 939-955.

[29] G. P. Solis, A. Kazemzadeh, L. Abrami, et al., “Local and Substrate-specific S-palmitoylation Determines Subcellular Localization of Gαo,” Nature Communications 13, no. 1 (2022): 2072.

[30] K. Nakamura, H. Kodera, T. Akita, et al., “De Novo Mutations in GNAO1, Encoding a Galphao Subunit of Heterotrimeric G Proteins, Cause Epileptic Encephalopathy,” American Journal of Human Genetics 93, no. 3 (2013): 496-505.

[31] M. Thiel, D. Bamborschke, W. G. Janzarik, et al., “Genotype-phenotype Correlation and Treatment Effects in Young Patients with GNAO1-Associated Disorders,” Journal of Neurology, Neurosurgery, and Psychiatry 94, no. 10 (2023): 806-815.

[32] Y. A. Larasati, M. Thiel, A. Koval, D. N. Silachev, A. Koy, and V. L. Katanaev, “Zinc for GNAO1 Encephalopathy: Preclinical Profiling and a Clinical Case,” Med 6, no. 1 (2025): 100495.

[33] S. Richards, N. Aziz, S. Bale, et al., “Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,” Genetics in Medicine 17, no. 5 (2015): 405-424.

[34] T. H. Lan, Q. Liu, C. Li, G. Wu, and N. A. Lambert, “Sensitive and High Resolution Localization and Tracking of Membrane Proteins in Live Cells With BRET,” Traffic (Copenhagen, Denmark) 13, no. 11 (2012): 1450-1456.

[35] M. Saraste, P. R. Sibbald, and A. Wittinghofer, “The P-Loop-a Common Motif in ATP- and GTP-binding Proteins,” Trends in Biochemical Sciences 15, no. 11 (1990): 430-434.

[36] A. B. Seven, D. Hilger, M. M. Papasergi-Scott, et al., “Structures of Gα Proteins in Complex With Their Chaperone Reveal Quality Control Mechanisms,” Cell Reports 30, no. 11 (2020): 3699-3709.e6.

[37] L. J. McClelland, K. Zhang, T. C. Mou, et al., “Structure of the G Protein Chaperone and Guanine Nucleotide Exchange Factor Ric-8A Bound to Gαi1,” Nature Communications 11, no. 1 (2020): 1077.

[38] V. L. Katanaev, “Gln52 mutations in GNAO1-related Disorders and Personalized Drug Discovery,” Epilepsy & Behavior Reports 24 (2023): 100598.

[39] V. L. Katanaev, “Humanization for Neurological Disease Modeling: A Roadmap to Increase the Potential of Drosophila Model Systems,” Animal Models and Experimental Medicine 6, no. 3 (2023): 230-236.

[40] A. Członkowska, T. Litwin, P. Dusek, et al., “Wilson Disease,” Nature Reviews Disease Primers 4, no. 1 (2018): 21.

[41] A. M. Grabrucker, M. Rowan, and C. C. Garner, “Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review,” Drug Delivery Letters 1, no. 1 (2011): 13-23.

[42] M. Di Rocco, S. Galosi, F. C. Follo, et al., “Phenotypic Assessment of Pathogenic Variants in GNAO1 and Response to Caffeine in C. elegans Models of the Disease,” Genes (Basel) 14, no. 2 (2023): 319.

[43] D. Silachev, A. Koval, M. Savitsky, et al., “Mouse Models Characterize GNAO1 Encephalopathy as a Neurodevelopmental Disorder Leading to Motor Anomalies: From a Severe G203R to a Milder C215Y Mutation,” Acta Neuropathologica Communications 10, no. 1 (2022): 9.

[44] H. Schihada, R. Shekhani, and G. Schulte, “Quantitative Assessment of Constitutive G Protein-Coupled Receptor Activity With BRET-based G Protein Biosensors,” Science Signaling 14, no. 699 (2021): eabf1653.

[45] D. P. McEwen, K. R. Gee, H. C. Kang, and R. R. Neubig, “Fluorescent BODIPY-GTP Analogs: Real-Time Measurement of Nucleotide Binding to G Proteins,” Analytical Biochemistry 291, no. 1 (2001): 109-117.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.